surmount-1 tirzepatide weight loss percent nejm 2022 SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions π Semaglutide 2.4mg: β13.7% weight
Pay in 4 interest-free payments of $7.21 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17

















)





